|
|
| July 2, 2009 |
 
BNA® News |
CMS Plans to Step Up Surveillance During Upcoming Enrollment Period
The Centers for Medicare & Medicaid Services plans
to increase its surveillance of marketing activities and beneficiary
complaints involving Medicare Advantage and prescription drug plans
for the upcoming enrollment period, an agency official said June 24 at
a conference on Medicare compliance issues. From Health Plan & Provider Report, Publication date July 1, 2009
Link to Story
OIG Says No Sanctions for Hospital's Plan to Share Part of Cost Savings With Doctors
An agreement by a hospital to share part of its cost savings with
three groups of physicians could constitute an improper payment, but
the Department of Health and Human Services Office of Inspector
General said it would not impose sanctions, according to an advisory
opinion (No. 09-06) posted June 30. From Health Care Daily Report, Publication date July 1, 2009
Link to Story
Federal Prosecutors Say Device Makers Face Different Issues Than Pharma Industry
While the rules governing them may be similar, the medical devices
industry and the pharmaceuticals industry are different, and the
differences may impact the way the rules are applied to each, two
federal prosecutors said June 15 at the Center for Business
Intelligence's Fifth Annual Medical Device and Diagnostic Marketing
Compliance Congress in Arlington, Va. From Medical Devices Law & Industry Report, Publication date July 1, 2009
Link to Story
Group Says Stimulus Bill Privacy Provisions May Limit Comparative Effectiveness Studies
The economic stimulus bill provided more than $1 billion for
comparative effectiveness research, but the legislation also included
language on the privacy rule that inadvertently could discourage such
research, Douglas Peddicord, executive director of the Association of
Clinical Research Organizations, told BNA June 18. From Medical Research Law & Policy ReportŪ, Publication date July 1, 2009
Link to Story
FTC Says Drug Prices Reduced By Presence of Authorized Generics
Drug prices are lower when “authorized” generic drugs
from brand-name companies are marketed in competition with a single
generic drug, compared to when one company has generic market
exclusivity, the Federal Trade Commission June 24 said in an interim
report. From Pharmaceutical Law & Industry ReportŪ, Publication date June 26, 2009
Link to Story
AMA Resolution Backs Health System Reform, but Deletes Reference to Public Plan Option
After lengthy and often divisive debate over the specific
wording of how much to support the movement toward health care reform,
the American Medical Association House of Delegates June 17 passed a
resolution, but deleted any reference to a public plan option. From Health Care Policy Report, Publication date June 22, 2009
Link to Story
Drug Industry Pledges to Cut Costs for Enrollees in Part D Coverage Gap
The industry group representing large pharmaceutical manufacturers
announced June 20 an agreement to discount drugs for enrollees in the
Medicare Part D drug benefit whose high expenses have caused them to
enter the coverage gap. From Medicare Drug Watch, Publication date June 23, 2009
Link to Story
Life Sciences Companies Cite FTC Actions as Reason for Scrapping Planned Mergers
A medical device manufacturer and a supplier of plasma-derivative
protein independently announced they were halting planned mergers due
to actions by the Federal Trade Commission, the first because the
agency was taking too long to close its review and the second because
of an FTC suit to block the merger. From Life Sciences Law & Industry Report, Publication date June 19, 2009
Link to Story
MedPAC Report Examines Imaging Incentives When Doctors Own Equipment
When physicians have a financial interest in imaging equipment,
they are more likely to order imaging tests and incur higher overall
spending on their patients' care, the Medicare Payment Advisory
Commission said in its June report to Congress June 15. From Health Care Fraud Report, Publication date June 17, 2009
Link to Story
|
|
Archive
|
|
|